Thymol as Biofilm and Efflux Pump Inhibitor: A Dual‐Action Approach to Combat Mycobacterium tuberculosis

• Published in: Cell biochemistry and function Vol. 42; no. 8; pp. e70030 - n/a
• Main Authors: Shankar Das, Bhabani, Sarangi, Ashirbad, Pahuja, Isha, Singh, Vishal, Ojha, Suvendu, Giri, Sidhartha, Bhaskar, Ashima, Bhattacharya, Debapriya
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.12.2024
• Subjects: Antitubercular Agents - chemistry; Antitubercular Agents - pharmacology; anti‐biofilm activity; anti‐sliding activity; Bacterial Proteins - antagonists & inhibitors; Bacterial Proteins - metabolism; Biofilms; Biofilms - drug effects; Biological activity; Computer applications; Drug resistance; Effectiveness; Efflux; EPI activity; Global health; In vitro methods and tests; Inhibitors; Isoniazid; Isoniazid - pharmacology; Medical innovations; Membrane Transport Proteins - metabolism; Microbial Sensitivity Tests; Molecular Docking Simulation; Motility; Mycobacterium smegmatis - drug effects; Mycobacterium smegmatis - metabolism; Mycobacterium tuberculosis; Mycobacterium tuberculosis - drug effects; Mycobacterium tuberculosis - metabolism; Oxygen; Pharmacokinetics; Pharmacology; Phenolic compounds; Phenols; Porins; Proteins; Public health; Reactive oxygen species; Reactive Oxygen Species - metabolism; Rifampin; Rifampin - pharmacology; ROS activity; Synergistic effect; Thymol; Thymol - chemistry; Thymol - pharmacology; Tuberculosis; Verapamil; thymol; ROS activity; anti‐biofilm activity; anti‐sliding activity; EPI activity

ABSTRACT Tuberculosis (TB) remains a significant global health challenge, exacerbated by the emergence of drug‐resistant strains of Mycobacterium tuberculosis (M. tb). The complex biology of M. tb, particularly its key porins, contributes to its resilience against conventional treatments, highlighti...